Developments in the field of biotechnology have been categorized into three ‘waves’ or stages. In the first stage or the ‘green wave’, the industry was dominated by the agricultural applications of biotechnology. This was followed by medical applicat ....see more
The global Cell & Gene Therapy Manufacturing Services Market in terms of revenue was estimated to be worth $5.1 billion in 2022 and is poised to reach $11.5 billion by 2027, growing at a CAGR of 17.5% from 2022 to 2027. Some of the prominent players in the global market are Lonza (Switzerland), Catalent (US), Thermo Fisher Scientific (US), Charles River Laboratories (US WuXi AppTec (China), Merck KGaA (Germany), Takara Bio Inc. (Japan), Nikon Corporation (Japan), FUJIFILM Holdings Corporation (Japan), Oxford Biomedica plc (UK), and Cell and Gene Therapy Catapult (UK).
The global next generation sequencing market in terms of revenue was estimated to be worth $13 billion in 2022 and is poised to reach $27 billion by 2027, growing at a CAGR of 15.7% from 2022 to 2027. Prominent players in this market are Illumina (US), Thermo Fisher Scientific (US), PerkinElmer (US), BGI Group (China), Agilent Technologies (US), Eurofins Scientific (Luxembourg), Pacific Biosciences (US), Oxford Nanopore Technologies (UK), QIAGEN (Netherlands), F. Hoffmann-La Roche AG (Switzerland), Brooks Automation (US), Psomagen, Inc. (US), 10x Genomics (US), Tecan Group (Switzerland), Zymo Research (US), Takara Bio (Japan), Promega Corporation (US), CD Genomics (US), New England Biolabs (US), and Novogene Corporation (China).
The global biologics safety testing market in terms of revenue was estimated to be worth $3.6 billion in 2022 and is poised to reach $6.8 billion by 2027, growing at a CAGR of 13.3% from 2022 to 2027. Prominent players in the biologics safety testing market are Charles River Laboratories, Inc. (US), Lonza (Switzerland), Thermo Fisher Scientific, Inc. (US), Merck KGaA (Germany), SGS SA (Switzerland), WuXi AppTec (China), Labcorp (US) and Eurofins Scientific (Luxembourg). The key players in this market are focusing on strategic expansions, partnerships, and product & service launches to expand their presence in the market.
The APAC in situ hybridization market size is Projected to grow from USD 363 million in 2022 to reach USD 744 million by 2027, at a CAGR of 15.4% during the forecast period. The Asia Pacific in situ hybridization market is consolidated in nature with prominent players in the in situ hybridization market including Abbott Laboratories (US), Thermo Fisher Scientific (US), Danaher Corporation (US), Merck (Germany), F. Hoffmann-La Roche (Switzerland), BioView (Israel), Agilent Technologies (US), Biocare Medical (US), Bio-Techne Corporation (US), QIAGEN (Germany), PerkinElmer (US), Enzo Biochem (US), Bio-Rad Laboratories (US), Abnova Corporation (Taiwan), BioGenex Laboratories (US), OpGen (US), Bio SB (US), Abcam (UK), Zytomed (Germany), 10x Genomics Inc. (US), and NeoGenomics Laboratories (US).
The APAC spatial genomics & transcriptomics market is expected to grow from USD 64 million in 2022 to USD 152 million by 2027, at a CAGR of 18.9% during the forecast period. The market for Asia Pacific spatial genomics & transcriptomics is highly consolidated, with key players strategizing to capture the market. Prominent players in the Asia Pacific spatial genomics and transcriptomics market are NanoString Technologies, Inc. (US), 10X Genomics (US), Illumina (US), Bio-Rad Laboratories (US), Bio-Techne Corporation (US), Standard BioTools Inc. (US), Akoya Biosciences, Inc. (US), PerkinElmer, Inc. (US), S2 Genomics, Inc. (US), Cantata Bio (US), Vizgen Corporation (US), BGI (China), Miltenyi Biotec (Germany), Bruker (US), PerkinElmer Inc. (US), and Novogene Co., Ltd. (China).
The spatial genomics & transcriptomics market is expected to grow from USD 355 million in 2022 to USD 800 million by 2027, at a CAGR of 17.6% during the forecast period. The spatial genomics & transcriptomics market is consolidated in nature with prominent players in the spatial genomics & transcriptomics market include NanoString Technologies, Inc. (US), 10X Genomics (US), Illumina (US), Bio-Rad Laboratories (US), Bio-Techne Corporation (US), Standard BioTools Inc. (US), Genomic Vision SA (France), Akoya Biosciences, Inc. (US), Danaher Corporation (US), Natera, Inc. (US), PerkinElmer, Inc. (US), Seven Bridges Genomics (US), S2 Genomics, Inc. (US), Cantata Bio (US), Vizgen Corporation (US), BioSpyder Technologies Inc. (US), Optical Biosystems Inc. (US), Miltenyi Biotec (Germany), Ultivue Inc. (US), Lunaphore Technologies SA (Switzerland), Rebus Biosystems LLC (US), Resolve Biosciences (Germany), Singular Genomics, Inc. (US), and Veracyte (US).
The regenerative medicine market is projected to reach USD 40.6 billion by 2027, at a CAGR of 27.2% during the forecast period. Global players operating in this market are include Novartis AG (Switzerland), Biogen (US), Sarepta Therapeutics, Inc. (US), Gilead Sciences, Inc. (US), Amgen, Inc. (US), Smith & Nephew plc (UK), Medipost Co., Ltd. (South Korea), JCR Pharmaceuticals Co., Ltd (Japan), Takeda Pharmaceutical Company (Japan), CORESTEM, Inc (South Korea), Vericel Corporation (US), MIMEDX (US), Organogenesis Inc. (US), Medtronic plc (US), Orthocell Ltd. (Australia), Mesoblast Ltd (Australia), BioRestorative Therapies, Inc (US), Pluri Inc. (Israel), Tegoscience (South Korea), Anterogen Co., Ltd. (South Korea), bluebird bio, Inc. (US), APAC Biotech (India), Shenzhen SiBiono Genetech Co., Ltd. (China), Aspect Biosystems (Canada), and Athersys, Inc. (US).
The latin american flow cytometry market size is projected to reach USD 379 million by 2027, at a CAGR of 7.1% during the forecast period. Key players in this market are Becton, Dickinson and Company (US), Danaher Corporation (US), Thermo Fisher Scientific, Inc. (US), Agilent Technologies, Inc. (US), Bio-Rad Laboratories, Inc. (US), Miltenyi Biotec GmbH (Germany), Cytek Biosciences, Inc. (US), and Luminex Corporation (US).
The oligonucleotide synthesis market is expected to grow from USD 7.7 billion in 2022 to USD 16.7 billion by 2027, at a CAGR of 16.8% during the forecast period. Some leading players operating in the oligonucleotide synthesis market are Danaher Corporation (US), Thermo Fisher Scientific, Inc. (US), Merck KGaA (Germany), LGC Limited (UK), Maravai Life Sciences (US), and Agilent Technologies, Inc. (US).
The global recombinant proteins market in terms of revenue was estimated to be worth $1.4 billion in 2022 and is poised to reach $2.4 billion by 2027, growing at a CAGR of 11.4% from 2022 to 2027. The prominent players operating in this market includes Thermo Fisher Scientific Inc. (US), Miltenyi Biotech (Germany), Sino Biological Inc. (China), Merck KGaA (Germany), Abcam plc (UK), Biolegend (US), Bio-Rad Laboratories, Inc. (US), GenScript Biotech Corporation (China), Enzo Life Sciences, Inc. (US), BPS Bioscience, Inc. (US), Proteintech Group, Inc. (US), Abnova Corporation (Taiwan), R&D Systems (US), STEMCELL Technologies Inc (Canada), Other players operating in the market include RayBiotech Inc (US), CellGenix GmbH (Germany), ACROBiosystems (US), ProSpec-TechnoGene Ltd. (Israel), Neuromics (US), Laurus Bio (India), Icosagen AS (US), ProteoGenix (France), United States Biological (US), StressMarq Biosciences Inc (Canada), and Aviva Systems Biology Corporation (US).
The global In situ hybridization market in terms of revenue was estimated to be worth $1.5 billion in 2022 and is poised to reach $2.8 billion by 2027, growing at a CAGR of 12.6% from 2022 to 2027. Some of the prominent players in this market are Abbott (US), Abcam (UK), Abnova Corporation (Taiwan), Agilent Technologies, Inc. (US), Bio SB Inc. (US), Biocare Medical, LLC (US), BioCat GmbH (Germany), BioGenex Laboratories (US), Bio-Rad Laboratories (US), Bio-Techne Corporation (US), BioView (Israel), Creative Bioarray (US), Danaher (US), Enzo Biochem (US), F. Hoffmann-La Roche AG (Switzerland), GeneMed Biotechnologies Inc. (US), Merck KGaA (Germany), NeoGenomics Laboratories (US), OpGen (US), Oxford Gene Technology (UK), PerkinElmer Inc. (US), QIAGEN N.V. (Netherlands), Thermo Fisher Scientific (US), and ZytoVision GmbH (Germany).
The glycomics/ glycobiology market size is projected to reach USD 3.7 billion by 2027, at a CAGR of 15.5% during the forecast period. Key players in the glycomics/ glycobiology market are Thermo Fisher Scientific (US), New England Biolabs (US), Merck KGaA (Germany), Promega Corporation (US), Waters Corporation (US), Takara Bio Inc, (Japan), Bio-Techne (US), Agilent Technologies (US), Sumitomo Bakelite Co. Ltd. (Japan), Bruker Corporation (US), Shimadzu Corporation (Japan), Danaher Corporation (US), AMS Bio (UK), Ludger Ltd (UK), Z Biotech, LLC (US), Chemily Glycoscience (US), CD BioGlyco (US), GlycoDiag (France), Kode Biotech Limited (New Zealand), Glyxera GmBH (Germany), Lectenz Bio (US), Glycomix Ltd (UK), IEC Group (Italy), Asparia Glycomics (Spain) and Ray Biotech Life Inc. (US).
The global protein expression market in terms of revenue was estimated to be worth $2.9 billion in 2022 and is poised to reach $5.4 billion by 2027, growing at a CAGR of 13.3% from 2022 to 2027. Key players in the Protein Expression market include Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), GenScript Biotech Corporation (US), Agilent Technologies Inc. (US), Danaher Corporation (US), Sartorius AG (Germany), Takara Bio Inc. (Japan), Bio-Rad Laboratories Inc. (US), Lonza Group AG (Switzerland), Promega Corporation (US), New England Biolabs (US), and Oxford Expression Technologies Ltd. (UK).
The global Single Use Assemblies Market in terms of revenue was estimated to be worth $2.7 billion in 2022 and is poised to reach $6.5 billion by 2027, growing at a CAGR of 18.8% from 2022 to 2027. The prominent players in this market are Thermo Fisher Scientific, Inc. (US), Sartorius Stedim Biotech (France), Danaher Corporation (US), Merck KGaA (Germany), and Avantor, Inc. (US).
The global stem cell therapy market in terms of revenue was estimated to be worth $257 million in 2022 and is poised to reach $558 million by 2027, growing at a CAGR of 16.8% from 2022 to 2027.. The global market is consolidated in nature with prominent players in the include Smith+Nephew (UK), MEDIPOST Co., Ltd. (South Korea), Anterogen Co., Ltd. (South Korea), CORESTEM (South Korea), Pharmicell Co., Ltd. (South Korea), NuVasive, Inc. (US), RTI Surgical (US), AlloSource (US), JCR Pharmaceuticals Co., Ltd. (Japan), Takeda Pharmaceutical Company Limited (Japan), Holostem Terapie Avanzate Srl (Italy), Orthofix (US), Regrow Biosciences Pvt Ltd. (India), and STEMPEUTICS RESEARCH PVT LTD. (India).
The global vaccine adjuvants market in terms of revenue was estimated to be worth $1.5 billion in 2022 and is poised to reach $1.6 billion by 2027, growing at a CAGR of 1.7% from 2022 to 2027. Key players in the vaccine adjuvants market include GSK plc (UK), Dynavax Technologies (US), Novavax (US), Agenus Inc. (US), Croda International plc (UK), Seppic (France), OZ Biosciences (US), Phibro Animal Health Corporation (US), Associated British Foods plc (UK), InvivoGen (US), Merck KGaA (Germany), CSL Limited (Australia), Vertellus (US), Allergy Therapeutics (UK), Riboxx GmbH (Germany).
The global flow cytometry market in terms of revenue was estimated to be worth $4.7 billion in 2022 and is poised to reach $6.9 billion by 2027, growing at a CAGR of 8.1% from 2022 to 2027. The prominent players in this market are Becton, Dickinson and Company (US), Danaher Corporation (US), Thermo Fisher Scientific, Inc. (US), Agilent Technologies, Inc. (US), and Luminex Corporation (US).
The global neuromodulation market in terms of revenue was estimated to be worth $6.0 billion in 2022 and is poised to reach $10.4 billion by 2027, growing at a CAGR of 11.8% from 2022 to 2027. The major players operating in this market are Medtronic (Ireland), Boston Scientific Corporation (US), Abbott Laboratories (US), and LivaNova (UK).
The cell therapy technologies market is expected to grow from USD 4.0 billion in 2022 to USD 8.0 billion by 2027, at a CAGR of 14.6% during the forecast period. Key players in the Market include Thermo Fisher Scientific, Inc. (US), Merck KGaA (Germany), Danaher Corporation (US), Lonza Group (Switzerland), Sartorius AG (Germany), Terumo BCT (US), Becton, Dickinson and Company (US), Fresenius SE & Co. KGaA (Germany), Avantor, Inc. (US), Bio-Techne Corporation (US), Corning Incorporated (US), FUJIFILM Irvine Scientific (US), MaxCyte Inc. (US), Werum IT Solutions GmbH (Germany), RoosterBio Inc. (US), SIRION Biotech GmbH (Germany), TrakCel (UK), L7 Informatics, Inc. (US), Miltenyi Biotec GmbH (Germany), STEMCELL Technologies (Canada), GPI Iberia (Spain), MAK-SYSTEM (US), OrganaBio, LLC (US), IxCells Biotechnology (China), and Wilson Wolf Manufacturing Corporation (US).
The global Gene Therapy Market in terms of revenue was estimated to be worth $7.3 billion in 2022 and is poised to reach $17.2 billion by 2027, growing at a CAGR of 18.6% from 2022 to 2027. Key players in this market includes Biogen (US), Novartis AG (Switzerland), Gilead Sciences Inc. (US), and Sarepta Therapeutics (US).
The global efficacy testing market is projected to reach USD 423 million by 2027, at a CAGR of 6.1% during the forecast period. The prominent players in this market are Charles River Laboratories (US), WuXi AppTec (China), Eurofins Scientific (Luxembourg), SGS (Switzerland), Intertek Group (UK), Nelson Laboratories, LLC (a Sotera Health company, US), Microbac Laboratories, Inc. (US), Almac Group (UK), North American Science Associates, Inc. (US), Toxikon (US), Pacific Biolabs (US), MSL Solution Providers (UK), Intertek Group PLC (UK), Accugen Laboratories, Inc. (US), Consumer Product Testing Company (US), Lucideon (UK).
The global epigenetics market in terms of revenue was estimated to be worth $1.7 billion in 2022 and is poised to reach $3.9 billion by 2027, growing at a CAGR of 18.1% from 2022 to 2027. The prominent players operating in this market are Thermo Fisher Scientific (US), Merck KGaA (Germany), Illumina, Inc. (US), PacBio (US), Abcam plc (UK), Active Motif, Inc. (US), Bio-Rad Laboratories (US), Promega Corporation (US), PerkinElmer (US), Qiagen (Germany), New England Biolabs (US), Zymo Research Corporation (US), Diagenode (Germany), and F. Hoffmann-La Roche Ltd (Switzerland).
The global 3D bioprinting market in terms of revenue was estimated to be worth $1.3 billion in 2022 and is poised to reach $3.3 billion by 2027, growing at a CAGR of 20.8% from 2022 to 2027. Prominent players in the market are BICO Group AB (US), Organovo Holdings Inc. (US), Allevi, Inc. (part of 3D Systems, Inc.) (US), CollPlant Biotechnologies Ltd. (Israel), regenHU (Switzerland), EnvisionTEC GmbH (part of Desktop Metal, Inc.) (Germany), Aspect Biosystems Ltd. (Canada), Advanced Solutions Life Sciences, LLC (US), and Regenovo Biotechnology Co., Ltd. (part of Shining 3D Tech Co., Ltd.) (China).
The research antibodies & reagents market size is projected to reach USD 16.1 Billion by 2027, at a CAGR of 6.7% during the forecast period. The prominent market players are Thermo Fisher Scientific, Inc. (US), Merck KGaA (Germany), Abcam plc (UK), Becton, Dickinson, and Company (US), Bio-Rad Laboratories (US), Cell Signaling Technology (US), F. Hoffmann-La Roche (Switzerland), Danaher Corporation (US), Agilent Technologies (US), PerkinElmer (US), Lonza (Switzerland), GenScript (China), and BioLegend (US).
The global stem cell assays market is expected to grow from USD 1.9 billion in 2022 to USD 4.5 billion by 2027, at a compound annual growth rate (CAGR) of 17.7 % during the forecast period.The key players Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Danaher (US), Becton, Dickinson and Company (US), Bio-Rad Laboratories (US), PerkinElmer (US), Agilent Technologies (US), Promega Corporation (US), Cell Biolabs (US), Miltenyi Biotec (Germany), STEMCELL Technologies (Canada), Bio-Techne Corporation (US), FUJIFILM Holdings Corporation (Japan), Charles River Laboratories (US), HemoGenix Inc. (US), Lonza Group (Switzerland), Takara Bio Inc. (Japan), Creative Bioarray (US), AAT Bioquest, Inc. (US), BPS Bioscience, Inc. (US), Enzo Biochem (US), PromoCell GmbH (Germany), Biotium (US), Geno Technology (US), Abcam plc (UK), and ReachBio Research Labs (US).
The global nucleic acid isolation and purification market is projected to reach USD 9.2 billion by 2027, at a CAGR of 7.9% during the forecast period. Key Players operating in this market are QIAGEN N.V. (Netherlands), Thermo Fisher Scientific (US), and F. Hoffmann-La Roche Ltd. (Switzerland) are the key players operating in the nucleic acid isolation and purification market. Other prominent players in this market include Promega Corporation (US), Agilent Technologies (US), Bio-Rad Laboratories (US), Danaher Corporation (US), GE Healthcare (US), Illumina, Inc. (US), Merck KGaA (Germany), Takara Bio (Japan), Zymo Research (US), New England Biolabs (US), Norgen Biotek Corp (Canada), Omega Bio-tek (US), Genaxxon Bioscience GmbH (Germany), 3B BlackBio Biotech India Limited (India), Invitek Molecular (Germany), BioVision (US), and Analytik Jena AG (Germany).
The global In Vitro Toxicology Testing Market boasts a total value of $11.2 billion in 2022 and is projected to register a growth rate of 10.8% to reach a value of $18.6 billion by 2027. The prominent players in the in vitro toxicology testing market include Thermo fisher Scientific, Inc. (US), Laboratory Corporation of America Holdings (US), Bio-Rad Laboratories, Inc. (US), General Electric Company (US), Eurofins Scientific (Luxembourg), Merck KGaA (Germany), Charles River Laboratories International, Inc. (US), Catalent, Inc. (US), Evotec (UK), SGS S.A. (Switzerland), QIAGEN (Germany), Promega Corporation (US), Gentronix Limited (UK), BioIVT (US), and MB Research Laboratories (US).
The global cell analysis market is projected to reach USD 28.6 billion by 2027, at a CAGR of 10.1% during the forecast period. The cell analysis market is fragmented in nature with prominent players operating in this market such as Danaher (US), Thermo Fisher Scientific (US), Becton, Dickinson and Company (US), General Electric (US), Merck KGaA (US), Agilent Technologies (US), Olympus Corporation (Japan), Miltenyi Biotec (US), Bio-Rad Laboratories (US), BioStatus Limited (UK), Fluidigm Corporation (US), NanoCellect Biomedical (US), Cell Biolabs (US), Creative Bioarray (US), Meiji Techno (US), Promega Corporation (US), PerkinElmer (US), Tecan Trading AG (Switzerland), CELLINK (US), QIAGEN (Germany), Corning Incorporated (US), 10x Genomics (US), and Illumina (US).
The global 3D cell culture market in terms of revenue was estimated to be worth $1.3 billion in 2022 and is poised to reach $2.6 billion by 2027, growing at a CAGR of 15.6% from 2022 to 2027. Prominent players in this market are Thermo Fisher Scientific (US), Merck KGaA (Germany), Corning Incorporated (US), Lonza Group AG (Switzerland), Avantor Inc. (US), Tecan Trading AG (Switzerland), REPROCELL Inc. (Japan), 3D Biotek LLC. (US), Emulate Inc. (US), CN Bio Innovations (UK), Synthecon Incorporated (US), and InSphero AG (Switzerland).
The global plasma fractionation market size is projected to reach USD 36.7 billion by 2027, at a CAGR of 6.7% during the forecast period. The plasma fractionation market is an oligopolistic market. The prominent players operating in this market include CSL (Australia), Grifols, S.A. (Spain), Shire (US), Octapharma AG (Switzerland), Kedrion S.P.A (Italy), LFB (France), Biotest AG (Germany), Sanquin (Netherlands), China Biologic Products Holdings Inc. (China), GC Pharma (Korea), Bio Products Ltd. (UK), Japan Blood Products Organization (Japan), Emergent BioSolutions (US), Shanghai Raas Blood Products Co., Ltd. (China), Intas Pharmaceuticals Ltd. (India), Bharat Serum Vaccines Limited (India).
The tangential flow filtration market is projected to reach USD 2.8 billion by 2027, at a CAGR of 13.2% during the forecast period. Key players in the Market include Merck KGaA (Germany), Danaher Corporation (US), Sartorius AG (Germany), Parker Hannifin Corporation (US), Repligen Corporation (US), Alfa Laval Corporate AB (Sweden), ANDRITZ (Austria), Meissner Filtration Products, Inc. (US), Cole-Parmer Instrument Company, LLC (US), Solaris Biotechnology Srl (Italy), Koch Separation Solutions (US), Sterlitech Corporation US), Synder Filtration, Inc. (US), PendoTECH (US), ARTeSYN Biosolutions (Ireland), Microfilt India Pvt. Ltd. (India), Bionet (Spain), SYSBIOTECH GmbH (Austria), Cobetter Filtration Equipment Co., Ltd. (China), Biotree (India), FORMULATRIX (US), Mantec Technical Ceramics Ltd. (UK), Smartflow Technologies (US), TAMI Industries (France), and SPF Technologies LLC (US).
The global Human Microbiome Market in terms of revenue was estimated to be worth $269 million in 2023 and is poised to reach $1,370 million by 2029, growing at a CAGR of 31.1% from 2023 to 2029. The major players Enterome Bioscience (France), Seres Therapeutics (US) 4D Pharma (UK), and Ferring Pharmaceuticals (Switzerland).
The metagenomic sequencing market is expected to grow from USD 1.9 billion in 2022 to USD 4.3 billion by 2027, at a compound annual growth rate (CAGR) of 18.4% during the forecast period.The leading players Illumina, Inc. (US), Thermo Fisher Scientific (US), QIAGEN N.V. (Netherlands), PerkinElmer, Inc. (US), and Oxford Nanopore Technologies Plc. (UK).
The exosome research market size is projected to reach USD 661 million by 2026, at a CAGR of 35.6%. Prominent players in this market are Thermo Fisher Scientific (US), System Biosciences (US), Bio-Techne (US), Lonza (Switzerland), QIAGEN N.V. (Germany), NX PharmaGen (US), Miltenyi Biotec (US), AMS Biotechnology (US), NanoSomiX (US), Norgen Biotek Corp. (US), Novus Biologicals (US), BioVision Inc. (US), Pall Corporation (US), Exopharm Limited (Australia), and EverZom (France).
The global Pharmaceutical Filtration market is projected to reach USD 29.7 billion by 2027, at a CAGR of 17.0% during the forecast period. Key players in the Pharmaceutical Filtration Market include Merck KGaA (Germany), Danaher Corporation (US), Sartorius AG (Germany), Parker-Hannifin Corporation (US), Thermo Fisher Scientific Inc. (US), 3M Company (US).
The global cell culture media market in terms of revenue was estimated to be worth $4.9 billion in 2021 and is poised to reach $10.3 billion by 2026, growing at a CAGR of 16.0% from 2021 to 2026. Key players in the market include Thermo Fisher Scientific, Inc. (US), Merck KGaA (Germany), Danaher Corporation (US), and Sartorius AG (Germany), Corning Incorporated (US).
The global Cell Culture Market in terms of revenue was estimated to be worth $22.8 billion in 2021 and is poised to reach $41.3 billion by 2026, growing at a CAGR of 12.6% from 2021 to 2026. The key players of this market are Thermo Fisher Scientific, Inc. (US), Merck KGaA (Germany), Danaher Corporation (US), and Sartorius AG (Germany).
The global peptide synthesis market in terms of revenue was estimated to be worth $515 million in 2021 and is poised to reach $730 million by 2026, growing at a CAGR of 7.2% from 2021 to 2026. Growth in this market is driven by the increasing use of peptides in pharmaceutical drugs, an increase in research activities and the availability of funding for R&D, and the development of advanced automated peptide synthesizers. However, the lack of a unified set of regulations for therapeutic peptides and the high cost of instruments are expected to restrain the growth of this market during the forecast period.
The global Virology Specimen Collection Market boasts a total value of $5.6 billion in 2021 and is projected to register a growth rate of -0.6% to reach a value of $5.4 billion by 2026. The major players operating in this market are Becton, Dickinson and Company (US), Quidel Corporation (US), Thermo Fisher Scientific, Inc. (US), Trinity Biotech (Ireland), Titan Biotech, Ltd. (India), Diasorin SA (Italy), Vircell S.L. (Spain), Copan Italia S.p.A. (Italy), Puritan Medical Products, Co. (Guilford, ME) and Hardy Diagnostics (US).
The global Genome Editing Market boasts a total value of $5.1 billion in 2021 and is projected to register a growth rate of 18.2% to reach a value of $11.7 billion by 2026. Prominent players in this market are Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), and GenScript (China).
The global western blotting market is projected to reach USD 1.4 billion by 2026, at a CAGR of 6.7% during the forecast period. Some of the leading players operating in the western blotting market are Bio-Rad Laboratories, Inc. (US), Thermo Fisher Scientific (US), Danaher Corporation (US), Bio-Techne Corporation (US), and Merck KGaA (Germany).
The global Immunohistochemistry market in terms of revenue was estimated to be worth $2.3 billion in 2021 and is poised to reach $3.3 billion by 2026, growing at a CAGR of 7.7% from 2021 to 2026. The Prominent players in this market are F. Hoffman-La Roche AG (Switzerland), Danaher Corporation (US), and Agilent Technologies, Inc. (US).
The global laboratory filtration market is projected to reach USD 5.3 billion by 2026, at a CAGR of 7.8% during the forecast period. The prominent players in the market are Merck Millipore (US), Danaher Corporation (US), Sartorius AG (Germany), 3M Company (US), GEA GROUP AKTIENGESELLSCHAFT (Germany), Steris (US), Thermo Fisher Scientific (US), Veolia Water Technologies (France), Avantor, Inc. (US), GVS S.p.A (Italy), MANN+HUMMEL (Germany), Agilent Technologies, Inc. (US), Ahlstrom-Munksjö (Finland), MACHEREY-NAGEL GmbH & Co. KG (Germany), AMD Manufacturing, Inc. (Canada), Koch Membrane Systems (US), Cole-Parmer (US), AQUAPORIN A/S (Denmark), and Sterlitech Corporation (US).
The Aptamers Market is projected to reach USD 342 million by 2026, at a CAGR of 17.7% during the forecast period. Some of the prominent players operating in this market include Aptamer Group (UK), Raptamer Discovery Group (US), SomaLogic Inc. (US), Aptamer Sciences, Inc. (South Korea) and Aptagen, LLC (US).
The animal growth promoters and performance enhancers market industry is projected to grow from USD 16.2 billion in 2021 and to reach USD 21.4 billion by 2026, at a Compound Annual Growth Rate (CAGR) of 5.7% during the forecast period. Prominent players in the Animal Growth Promoters and Performance Enhancers Market include are Cargill, Incorporated (US), Royal DSM N.V. (Netherlands), Elanco Animal Health Incorporated (US), Boehringer Ingelheim Group (Germany), Merck & Co., Inc (US), Alltech Corporation (US), Archer-Daniels-Midland Company (ADM) (US), Vetoquinol S.A. (France), Bupo Animal Health Pty Ltd. (South Africa) and Novus International, Inc. (US).
The bioprocess containers market size is projected to reach USD 9.6 billion by 2026, at a CAGR of 26.3%. The major players operating in this market are Sartorius Stedim Biotech (France), Thermo Fisher Scientific (US), Danaher Corporation (US), and Merck Millipore (Germany)
The protein characterization and identification market size is projected to reach USD 23.9 billion by 2026, at a CAGR of 13.7% during the forecast period. Thermo Fisher Scientific (US), Danaher Corporation (US), Merck KGaA (Germany), Agilent Technologies, Inc. (US), and Waters Corporation (US) are the prominent players operating in the protein characterization and identification market.
The global Single Cell Analysis Market in terms of revenue was estimated to be worth $3.1 billion in 2021 and is poised to reach $6.3 billion by 2026, growing at a CAGR of 15.1% from 2021 to 2026. The prominent players in the single-cell analysis market are Becton, Dickinson and Company (US), Danaher Corporation (US), Merck KGAA (Germany), QIAGEN N.V. (Netherlands), Thermo Fisher Scientific, Inc. (US), Promega Corporation (US), Illumina, Inc. (US), Fluidigm Corporation (US), 10X Genomics (US), and Corning Incorporated (US).
The global Single use Bioreactors Market boasts a total value of $3.4 billion in 2021 and is projected to register a growth rate of 21.1% to reach a value of $8.8 billion by 2026. The prominent players operating in this market are Sartorius Stedim Biotech (France), Thermo Fisher Scientific (US), Danaher Corporation (US), and Merck KGaA (Germany).
The global single use bioprocessing market in terms of revenue was estimated to be worth $8.2 billion in 2021 and is poised to reach $20.8 billion by 2026, growing at a CAGR of 20.5% from 2021 to 2026. Growth of this market is driven by factors such as the increasing demand for biopharmaceuticals and energy efficiency, the need to reduce water wastage and equipment floor space requirements, and the risk of cross-contamination. However, extractability and leachability issues regarding disposable components and environmental and economic concerns are the major factors restraining market growth.